Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021
Pete Kinross, Carlo Gagliotti, Hanna Merk, Diamantis Plachouras, Dominique L. Monnet, Liselotte Diaz Högberg, EARS-Net Study Group
Abstract
Recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show a large increase of +57% in Acinetobacter species bloodstream infections in the European Union and European Economic Area in the first years of the COVID-19 pandemic (2020–2021) compared with 2018–2019. Most were resistant to carbapenems, from intensive care units, and in countries with ≥ 50% carbapenem resistance in Acinetobacter spp. in 2018–2019. This highlights the requirement for reinforced Acinetobacter preparedness and infection prevention and control in Europe.
Topics & Concepts
AcinetobacterPandemicEuropean unionPreparednessInfection controlCoronavirus disease 2019 (COVID-19)CarbapenemIntensive careMedicineVirologyMicrobiologyBiologyIntensive care medicineAntibioticsInternal medicineInfectious disease (medical specialty)BusinessPolitical scienceInternational tradeLawDiseaseAntibiotic Use and ResistanceAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and Efficacy